Sensei Biotherapeutics Announces Major Restructuring: 46% Workforce Reduction and Closure of Rockville Research Site

Workforce Reduction:
Sensei Biotherapeutics is reducing its workforce by 46% as part of an organizational restructuring effort45.

Research Site Closure:
The company will close its Rockville research site to focus resources on the clinical development of SNS-10145.

Financial Position:
The restructuring aims to conserve cash, with the company's current cash position standing at $47.0 million, expected to fund operations into Q2 20265.

Clinical Development:
The Phase 1/2 dose expansion study for SNS-101 is approximately 50% enrolled, with clinical data expected in the first half of 20255.

Reason for Restructuring:
The move is intended to concentrate resources on the development of SNS-101, indicating a strategic shift in the company's priorities45.

Sources:

4. https://www.barchart.com/story/news/29592109/sensei-biotherapeutics-announces-organizational-restructuring-and-progress-on-sns-101-clinical-trials-with-data-expected-in-2025

5. https://www.stocktitan.net/news/SNSE/sensei-biotherapeutics-reports-third-quarter-2024-financial-results-6as4dlg3de5b.html